Abreva enters new markets
This article was originally published in The Tan Sheet
Executive SummaryCold sore remedy approved for OTC sale in Canada, could be available by year end under exclusive licensing agreement with GlaxoSmithKline, Avanir Pharmaceuticals says May 28. Deal with GSK, which was announced in March 2000 and also gave GSK U.S. marketing rights to Abreva, provides Avanir with royalties based on wholesale product revenue. Before GSK launches the docosanol 10% cream in Canada, firm must attain provincial approval from the national drug scheduling recommendation committee; GSK is scheduling a presentation before committee for September. Avanir also announces product approvals in Korea, Israel...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.